Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
8.30    -0.40 (-4.60%)
Bid:
8.10
Ask:
8.50
Spread: 0.40 (4.938%)
Market Cap: £57.14m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Form 8 (OPD)

11 Dec 2019 07:00

RNS Number : 4280W
hVIVO plc
11 December 2019
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

hVIVO plc ("hVIVO")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

n/a

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

hVIVO plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

06/12/2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES - Open Orphan Plc

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

Β 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

Β 

TOTAL:

Nil

Nil

Nil

Nil

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

Nil

Details, including nature of the rights concerned and relevant percentages:

Nil

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Β 

Interests of hVIVO Directors in hVIVO shares:

Name

No. of shares

%

Dr Trevor Phillips

44,776

0.05

James Winschel

154,548

0.19

Dr Mark Warne

5,677

0.01

Β 

Β Interests of hVIVO Directors in options over hVIVO shares:

Name

No. of options

Grant date

% vested

Expiry date

Exercise price (p)

Dr Trevor Phillips

850,000

20/12/17

nil

19/12/27

5p

Dr Trevor Nicholls

26,540

02/04/14

100

18/12/22

101.63p

Β 

Β 

Β 

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

11/12/2019

Contact name:

Anesh Patel (Interim Finance Director & Company Secretary)

Telephone number:

+44(0)207 148 1018

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
FEEUROBRKOAUAAA
Date   Source Headline
24th Aug 20237:00 amRNSNotice of Results
26th Jul 20237:00 amRNSTrading update
25th Jul 20237:00 amRNSFlu B challenge model
28th Jun 20237:00 amRNShMPV human challenge model
14th Jun 20238:00 amRNSDirector dealings
23rd May 202312:36 pmRNSResult of AGM
28th Apr 20237:00 amRNSAnnual Report and Notice of AGM
26th Apr 20237:00 amRNSFDA Breakthrough and Fast Track for US biotech
25th Apr 20237:00 amRNSFinal results
19th Apr 20237:10 amRNSNotice of Results
6th Apr 20233:54 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSPositive results from flu human challenge study
29th Mar 20237:00 amRNSPresentation at World Vaccine Congress
23rd Mar 20237:00 amRNSExercise of Options
16th Mar 20237:00 amRNSOmicron human challenge model update
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
6th Feb 20237:05 amRNSLong Term Incentive Plan / PDMR Notification
6th Feb 20237:00 amRNS£6.8m RSV human challenge contract signed
25th Jan 20239:06 amRNSSecond Price Monitoring Extn
25th Jan 20239:00 amRNSPrice Monitoring Extension
25th Jan 20237:00 amRNSTrading update
17th Jan 20237:00 amRNSEUR3.2m Venn contract with global pharma client
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
4th Jan 20237:00 amRNS£5.2m RSV contract and Notice of Trading update
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
3rd Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
19th Dec 20227:00 amRNSImutex Phase I data published
17th Nov 20222:05 pmRNSSecond Price Monitoring Extn
17th Nov 20222:00 pmRNSPrice Monitoring Extension
14th Nov 202211:15 amEQShVIVO hails growing contract values after winning £13.6mln RSV challenge trial deal
11th Nov 20227:00 amRNSExercise of Options
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20228:22 amRNS£13.6m RSV antiviral contract
4th Nov 20227:25 amRNSHolding(s) in Company
17th Jan 20208:01 amRNSRule 2.9 Announcement
17th Jan 20207:00 amRNSOffer Wholly Unconditional
15th Jan 20205:30 pmRNSOpen Orphan
15th Jan 20208:01 amRNSRule 2.9 Announcement
14th Jan 20207:00 amRNSSecond Closing of the Offer
13th Jan 20204:31 pmRNSExercise of Share Options
13th Jan 20201:39 pmRNSExercise of Share Options
13th Jan 20208:01 amRNSRule 2.9 Announcement
9th Jan 20201:29 pmRNSExercise of Share Options
8th Jan 20207:01 amRNSDirector's Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.